Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Daehwa Pharmaceutical Co., Ltd. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
A multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients with Essential Hypertension Inadequately Controlled with AGLS
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| AGSAVI | Experimental |
| |
| AGLS | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AGSAVI | Drug | Uptitation |
| |
| AGLS |
| Measure | Description | Time Frame |
|---|---|---|
| Change of MSSBP(Mean Sitting Systolic Blood Pressure) | Change of MSSBP(Mean Sitting Systolic Blood Pressure) From Baseline to Visit 5(For 10 weeks) | From Baseline(Visit 2) to Visit 5(For 10 weeks) |
Not provided
Not provided
Inclusion Criteria:
Hypertension patient who satisfied below condition at Visit 1.
patient who takes antihypertensive drug
patient who doesn't take antihypertensive drug
Hypertension patient who satisfied below condition at Visit 2.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| AhnGook | Seoul | South Korea |
Not provided
| ID | Term |
|---|---|
| D000075222 | Essential Hypertension |
| ID | Term |
|---|---|
| D006973 | Hypertension |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Uptitration |
|